Emer­gen­t's trou­bled Bal­ti­more site gets $100M up­grade

The US drug man­u­fac­tur­ing site most ar­guably in need of an up­grade is now get­ting one.

Emer­gent BioSo­lu­tions had al­ready sched­uled some main­te­nance at the ill-fat­ed Bayview site in Bal­ti­more, but now the CD­MO has pushed up that time­line to up­grade its fa­cil­i­ties. The im­prove­ments comes as Emer­gent awaits word from John­son & John­son which is cur­rent­ly as­sess­ing the fu­ture of its Covid-19 vac­cine pro­duc­tion in the US.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters